A Two-Part, Phase I Randomized, Double-Blind, Active-Comparator Controlled, Parallel Group Study to Assess the Pharmacokinetics, Safety, and Tolerability of MK-8808 and to Compare the Pharmacokinetics of MK-8808 With EU-approved MabThera® and US-licensed Rituxan® in Patients With Rheumatoid Arthritis (RA)
Phase of Trial: Phase I
Latest Information Update: 21 Jul 2016
At a glance
- Drugs Rituximab (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Merck & Co; Merck Sharp & Dohme
- 08 Jun 2016 Status changed from completed to discontinued by the Sponsor for business reasons.
- 09 May 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 06 Nov 2013 Planned end date changed from 1 May 2014 to 1 Apr 2014 as reported by ClinicalTrials.gov.